Charlotte, NC
Ketamine Therapy clinics in Charlotte
Charlotte has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. North Carolina permits ketamine under DEA registration and NCMB oversight. Most Charlotte clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in Charlotte only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in Charlotte, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in Charlotte sits in the standard range: single IV infusions run 500 to 900 dollars, a full 6 session protocol lands at 3,000 to 5,400, and Spravato copays depend on insurance coverage. A reputable Charlotte ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Three Strand Wellness
- Vitamin IV Therapy
- PRP Therapy
- IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
Mindpath Health Psychiatrists & Therapists
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
MindWell Health Charlotte (SouthPark) - Mental Health, Ketamine, and Spravato
- IV Therapy
- Ketamine Therapy
Flo Hydration & Wellness
- IV Therapy
- IV Hydration
- Ketamine Therapy
- Peptide Therapy
- Hormone Replacement Therapy (HRT)
Regulatory context
A note on North Carolina's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
HB 727 / Breakthrough Therapies Research Act (2023)
Proposed $5 million research grant for psilocybin and MDMA clinical studies at UNC institutions; pending. -
North Carolina Controlled Substances Act
Mirrors federal scheduling.
North Carolina enforces federal scheduling. The North Carolina Medical Board oversees prescriber conduct. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth rules. North Carolina's CSRS PDMP requires controlled substance reporting. UNC and Duke operate federally authorized clinical trials.